吉西他滨联合奥沙利铂方案治疗晚期胆囊癌与胆管癌临床观察

Gemcitabine and Oxaliplatin Combination Chemotherapy in Advanced Biliary Tract Cancers and Gallbladder Carcinoma

目的观察吉西他滨联合奥沙利铂方案治疗晚期胆囊癌和胆管癌临床疗效和毒副作用。方法 16例晚期胆囊癌和胆管癌患者,应用吉西他滨联合奥沙利铂方案化疗,即吉西他滨l 000 mg/m2,第1、第8天应用,奥沙利铂100mg/m2,第1天。每21天重复,直至出现不可耐受的副作用或肿瘤进展。结果 16例均可以进行疗效评价,CR 1例,PR 6例,SD 6例,PD3例,总有效率43.7%。中位生存期为12.8个月。不良反应主要为骨髓抑制、外周神经炎等。结论吉西他滨联合奥沙利铂方案治疗晚期胆囊癌和胆管癌近期疗效较好,不良反应有可以耐受性。可作为晚期胆囊癌和胆管癌的治疗选择。

Objective To evaluate the efficacy and safety of gemcitabine combined with oxaliplatin treatment in patients with locally advanced or metastatic gallbladder carcinoma and bile duct cancer. Methods Sixteen patients with locally advanced or metastatic GBC were treated with intravenous gemcitabine （1000mg/m2） over 30 min on days 1 and 8, 2 h infusion of oxaliplatin （ 100mg/m2） on day 1, repeated every 3 wk. Treatment was continued until occurrence of unacceptable toxicity or disease progression. Results 16 patients were evaluated. The objective remission rates （CR ＋PR）were 43.7%. The median overall survival for all the patients on study was 12. 8 months. the main toxicity were myelosuppression and peripheral neuropathy. Conclusion Gemcitabine plus oxaliplatin is a optional regimen for advanced gallbladder carcinoma and bile duct cancer.